Skip to content
Open access

A rapid point-of-care test for vancomycin monitoring at the clinical bedside

Jul 2026 · iScience · Vol 29, pp. 116064 · 0 citations · 79 references
Medicine

TL;DR

A competition-format microarray assay on a poly(oligo(ethylene glycol) methacrylate-co-glycidyl methacrylate-co-glycidyl methacrylate brush integrated into a single-use microfluidic cassette and portable reader to quantify vancomycin directly from fingerstick volumes of whole blood in 30 min.

Abstract

Summary Vancomycin requires individualized dosing guided by therapeutic drug monitoring, but current laboratory assays are slow and centralized. We describe a competition-format microarray assay on a poly(oligo(ethylene glycol) methacrylate-co-glycidyl methacrylate) brush integrated into a single-use microfluidic cassette and portable reader to quantify vancomycin directly from fingerstick volumes of whole blood in 30 min. The assay shows a limit of detection of 0.8 μg/mL and precise quantification across the clinical range, with relative error below 20%. In a pilot study of 31 patient samples, cassette measurements correlated strongly with routine hospital testing with minimal bias, including when operated by minimally trained coordinators. This work establishes an approach for rapid, decentralized vancomycin monitoring that could support area-under-the-curve-based dosing in settings where access to high-complexity laboratories is limited and suggests a path toward extending therapeutic drug monitoring to point-of-care devices.

Read PDF

Similar papers

Review Open access Jul 2026

Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy

This review aims to critically evaluate emerging bioanalytical platforms, modeling frameworks, and decision-support systems for optimizing TDM of last-resort antibiotics, and proposes a three-tiered TDM model combining site-specific sensing, real-time analysis, and computational forecasting to improve antimicrobial ste...

Aparna Inamdar, N. Beeraka, P. R. Hemanth Vikram et al. · 1 citation
Review Open access Jul 2026

Point-of-Care Molecular Diagnostics: Current Evidence and Future Perspectives

: Point-of-care molecular diagnostics (POC-MDx) have transformed infectious disease diagnosis by enabling rapid, accurate pathogen detection at or near the patient care site. Unlike conventional laboratory-based molecular tests, POC molecular platforms provide clinically actionable results within minutes to hours, faci...

Yogesh Kumar Gupta · 0 citations
Preprint Aug 2026

Whole Blood-Based Point-of-Care Assay for Single-Tier Lyme Disease Testing

A whole-blood multiplexed vertical flow assay (WB-xVFA) that performs single-tier Lyme serology directly from 50 microliter of whole blood is presented, demonstrating the feasibility of rapid, near-patient whole-blood Lyme serology.

Mihye Lee, R. Ghosh, Artem Goncharov et al. · 0 citations
Open access Jul 2026

A point-of-care test to measure tacrolimus directly from unprocessed whole blood

A novel point-of-care test, the TAC-D4 POCT, capable of measuring tacrolimus levels directly from whole blood samples without sample preparation steps or expensive analyzers with automated results available in 1-hour is described, helping overcome the current logistical barriers in the clinical management of patients r...

Damon T. Burrow, David S. Kinnamon, J. Heggestad et al. · 1 citation
Open access Jul 2026

Smartphone-connected, battery-free aptamer-based digital test for quantification of procalcitonin and monitoring of infection at the point of care

A battery-free, smartphone-connected electrochemical lateral flow assay with linked analytics for the detection of procalcitonin (ELLA-PCT) enabling quantitative testing at the point of care without conventional laboratory instrumentation, and has a strong potential to decentralise diagnosis of infectious diseases, sup...

Y. Cai, J. Flauzino, A. Şanli et al. · 0 citations
Open access Aug 2026

Absence of Interference on in vitro Clinical Diagnostic Assays Often Performed on Hospitalized Patients by Relmapirazin, a Fluorescent Tracer Agent for Point-of-Care Assessment of Glomerular Filtration Rate.

Investigation of possible interference this agent may induce with typical clinical diagnostic assays given to incoming and hospitalized patients found no interference from relmapirazin was detected in the suite of metabolic and cardiac assays evaluated.

R. Dorshow, N. Morrison, Margot Borgel · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.